Pub Date : 2022-07-01DOI: 10.1097/BS9.0000000000000118
Robert Peter Gale
{"title":"Chimeric antigen receptor-T-cell therapy: China leading the way.","authors":"Robert Peter Gale","doi":"10.1097/BS9.0000000000000118","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000118","url":null,"abstract":"","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"176"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10712767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1097/BS9.0000000000000126
Hao Zhang, Guoyu Meng
B-cell acute lymphoblastic leukemia (B-ALL) is a malignant tumor originating from B-lineage lymphoid precursor cells. The incidence of B-ALL is about 80% in childhood acute leukemia and 20% in adults. In recent years, with standardized treatment guided by risk stratification, the long-term disease-free survival rate of children is about 80%, while that of adults is less than 40%. However, the specific pathogenesis of the newly identified B-ALL and the targeted therapy strategies have not been vigorously investigated. In this review, we highlight the recent breakthroughs in mechanistic studies and novel therapeutic options in DUX4- and MEF2D-subtype B-ALLs.
{"title":"A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia.","authors":"Hao Zhang, Guoyu Meng","doi":"10.1097/BS9.0000000000000126","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000126","url":null,"abstract":"<p><p>B-cell acute lymphoblastic leukemia (B-ALL) is a malignant tumor originating from B-lineage lymphoid precursor cells. The incidence of B-ALL is about 80% in childhood acute leukemia and 20% in adults. In recent years, with standardized treatment guided by risk stratification, the long-term disease-free survival rate of children is about 80%, while that of adults is less than 40%. However, the specific pathogenesis of the newly identified B-ALL and the targeted therapy strategies have not been vigorously investigated. In this review, we highlight the recent breakthroughs in mechanistic studies and novel therapeutic options in DUX4- and MEF2D-subtype B-ALLs.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"161-163"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/87/ce/bs9-4-161.PMC9742090.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10731049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1097/BS9.0000000000000124
Li Han, Jianjun Chen, Rui Su
In eukaryotes, gene expression is highly orchestrated not only by genomic promoters and enhancers but also by covalent modifications added to either chromatin or RNAs. Traditionally, “epigenetics” refers to the chemical modifications that govern heritable changes in gene expression independent of the DNA sequence; “epitranscriptomics” indicates the covalent decorations in RNA, which plays a central role in posttranscriptional gene regulation. To date, >170 RNA chemical modifications have been characterized. Most of these modifications were originally identified in highly abundant noncoding RNA species, such as ribosomal RNAs (rRNAs), transfer RNAs (tRNAs), and small nuclear RNA (snRNAs). Recently, the substantial advances in high-throughput sequencing and analytical chemistry have enabled the precise detection and characterization of chemical modifications in messenger RNA (mRNA). Indeed, a consid- erable number of mRNA decorations have been documented, including N 6 -methyladenosine (m 6 A); N 1 -methyladenosine (m 1 A); N 6 ,2 ʹ -O-dimethyladenosine (m 6 A m ); 3-methylcytidine (m 3 C); 5-methylcytidine (m 5 C); 5-hydroxymethylcytidine (hm 5 C); N 4 -acetylcytidine (ac 4 C); Adenosine-to-inosine (A-to-I) editing; pseudouridine ( Ψ ); N 7 -methylguanosine (m 7 G) and 2 ʹ -O-methylated nucleotides (
{"title":"Epitranscriptomics in myeloid malignancies.","authors":"Li Han, Jianjun Chen, Rui Su","doi":"10.1097/BS9.0000000000000124","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000124","url":null,"abstract":"In eukaryotes, gene expression is highly orchestrated not only by genomic promoters and enhancers but also by covalent modifications added to either chromatin or RNAs. Traditionally, “epigenetics” refers to the chemical modifications that govern heritable changes in gene expression independent of the DNA sequence; “epitranscriptomics” indicates the covalent decorations in RNA, which plays a central role in posttranscriptional gene regulation. To date, >170 RNA chemical modifications have been characterized. Most of these modifications were originally identified in highly abundant noncoding RNA species, such as ribosomal RNAs (rRNAs), transfer RNAs (tRNAs), and small nuclear RNA (snRNAs). Recently, the substantial advances in high-throughput sequencing and analytical chemistry have enabled the precise detection and characterization of chemical modifications in messenger RNA (mRNA). Indeed, a consid- erable number of mRNA decorations have been documented, including N 6 -methyladenosine (m 6 A); N 1 -methyladenosine (m 1 A); N 6 ,2 ʹ -O-dimethyladenosine (m 6 A m ); 3-methylcytidine (m 3 C); 5-methylcytidine (m 5 C); 5-hydroxymethylcytidine (hm 5 C); N 4 -acetylcytidine (ac 4 C); Adenosine-to-inosine (A-to-I) editing; pseudouridine ( Ψ ); N 7 -methylguanosine (m 7 G) and 2 ʹ -O-methylated nucleotides (","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"133-135"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10731043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1097/BS9.0000000000000115
Ganiyu Olatunbosun Arinola, Elizabeth Disu, Adedokun Babatunde, Christopher Olopade, Olufunmilayo Olopade
Children with sickle cell disease (SCD) are particularly prone to pneumococcal infection and administration of Prevenar 13 pneumococcal vaccine in Nigerian children with SCD is yet to be wide spread. This call for the need to study humoral immune responses stimulated by Prevenar 13 pneumococcal vaccine in SCD children to confirm the benefit or otherwise for the use of Prevenar 13 pneumococcal vaccine.
Method: The levels of humoral (innate and adaptive) immune factors and associated nutritionally essential trace elements were determined following Prevenar 13 pneumococcal vaccination of 23 Nigerian children with SCD. Serum innate humoral immune factors [Complement factors (C1q and C4), transferrin, ferritin, and C-reactive protein (CRP)] and adaptive humoral immune factors [IgG, IgA, IgM, and IgE] were determined using ELISA. Nutritionally essential trace elements such as iron (Fe), copper (Cu), and zinc (Zn) were measured also using an atomic absorption spectrophotometer.
Results: The serum levels of certain innate humoral immune factors (ferritin, CRP, and C4), only one adaptive humoral immune factors (IgE), and essential trace elements (Fe, Zn, and Cu) were significantly elevated in children with SCD post Prevenar 13 pneumococcal vaccination when compared to prevaccination levels.
Conclusion: Vaccination of children with SCD with Prevenar 13 pneumococcal vaccine was associated with increased levels of more innate humoral immune factors than adaptive factors. This study thus supports the administration of Prevenar 13 pneumococcal vaccination to children with SCD.
{"title":"Assessment of humoral immunity and nutritionally essential trace elements in steady-state sickle cell disease Nigerian children before and after <i>Prevenar 13</i> pneumococcal vaccination.","authors":"Ganiyu Olatunbosun Arinola, Elizabeth Disu, Adedokun Babatunde, Christopher Olopade, Olufunmilayo Olopade","doi":"10.1097/BS9.0000000000000115","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000115","url":null,"abstract":"<p><p>Children with sickle cell disease (SCD) are particularly prone to pneumococcal infection and administration of <i>Prevenar</i> 13 pneumococcal vaccine in Nigerian children with SCD is yet to be wide spread. This call for the need to study humoral immune responses stimulated by <i>Prevenar 13</i> pneumococcal vaccine in SCD children to confirm the benefit or otherwise for the use of <i>Prevenar 13</i> pneumococcal vaccine.</p><p><strong>Method: </strong>The levels of humoral (innate and adaptive) immune factors and associated nutritionally essential trace elements were determined following <i>Prevenar 13</i> pneumococcal vaccination of 23 Nigerian children with SCD. Serum innate humoral immune factors [Complement factors (C1q and C4), transferrin, ferritin, and C-reactive protein (CRP)] and adaptive humoral immune factors [IgG, IgA, IgM, and IgE] were determined using ELISA. Nutritionally essential trace elements such as iron (Fe), copper (Cu), and zinc (Zn) were measured also using an atomic absorption spectrophotometer.</p><p><strong>Results: </strong>The serum levels of certain innate humoral immune factors (ferritin, CRP, and C4), only one adaptive humoral immune factors (IgE), and essential trace elements (Fe, Zn, and Cu) were significantly elevated in children with SCD post <i>Prevenar 13</i> pneumococcal vaccination when compared to prevaccination levels.</p><p><strong>Conclusion: </strong>Vaccination of children with SCD with <i>Prevenar 13</i> pneumococcal vaccine was associated with increased levels of more innate humoral immune factors than adaptive factors. This study thus supports the administration of <i>Prevenar 13</i> pneumococcal vaccination to children with SCD.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"170-173"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10706565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1097/BS9.0000000000000127
Mingzheng Hu, Yijie Wang, Jun Zhou
Defects in centrosomes are associated with a broad spectrum of hematological malignancies, such as leukemia and lymphoma. Centrosomes in these malignancies display both numerical and structural aberrations, including alterations in the number and size of centrioles, inappropriate post-translational modification of centrosomal proteins, and extra centrosome clustering. There is accumulating evidence that centrosome defects observed in hematological malignancies result from multiple factors, including dysregulation of the centrosome cycle and impairment of centriole biogenesis. In this review, we discuss the plausible mechanisms of centrosome defects and highlight their consequences in hematological malignancies. We also illustrate the latest therapeutic strategies against hematological malignancies by targeting centrosome anomalies.
{"title":"Centrosome Defects in Hematological Malignancies: Molecular Mechanisms and Therapeutic Insights.","authors":"Mingzheng Hu, Yijie Wang, Jun Zhou","doi":"10.1097/BS9.0000000000000127","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000127","url":null,"abstract":"<p><p>Defects in centrosomes are associated with a broad spectrum of hematological malignancies, such as leukemia and lymphoma. Centrosomes in these malignancies display both numerical and structural aberrations, including alterations in the number and size of centrioles, inappropriate post-translational modification of centrosomal proteins, and extra centrosome clustering. There is accumulating evidence that centrosome defects observed in hematological malignancies result from multiple factors, including dysregulation of the centrosome cycle and impairment of centriole biogenesis. In this review, we discuss the plausible mechanisms of centrosome defects and highlight their consequences in hematological malignancies. We also illustrate the latest therapeutic strategies against hematological malignancies by targeting centrosome anomalies.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"143-151"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/7c/bs9-4-143.PMC9742116.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10712766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To investigate the risk factors for cytomegalovirus (CMV) infection within 100 days and the relationship between early CMV infection and 1-year relapse for patients with acute leukemia following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Methods: Three hundred fifty-nine patients with acute leukemia who received allo-HSCT at our center between January 2015 and January 2020 were retrospectively reviewed.
Results: Of 359 patients, 48.19% (173) patients experienced CMV infection within 100 days posttransplantation. In univariate and multivariate logistic analysis, haploidentical-related donor (HRD) (P < 0.001; odds ratio [OR], 5.542; 95% confidence interval [CI], 3.186-9.639), and ratio of CD3+CD8+ cells in lymphocytes <14.825% (P < 0.001; OR, 3.005; 95% CI, 1.712-5.275) were identified as 2 independent risk factors. One-year relapse rate (RR) between the CMV infection group and the non-CMV infection group was not statistically significant (18.5% vs 19.9%, P = 0.688). When we divided the total cohort into AML, ALL, and MAL subgroups, there were no significant differences as well (P = 0.138; P = 0.588; P = 0.117; respectively).
Conclusion: In conclusion, donor type (HRD) and the insufficient recovery of CD3+CD8+ cells were independent risk factors for CMV infection within 100 days posttransplantation in patients with acute leukemia. CMV infection within 100 days did not influence the incidence of relapse in 1 year for patients with acute leukemia.
{"title":"Risk factors for CMV infection within 100 days posttransplantation in patients with acute leukemia.","authors":"Juan Chen, Aiming Pang, Yuanqi Zhao, Li Liu, Runzhi Ma, Jialin Wei, Xin Chen, Yi He, Donglin Yang, Rongli Zhang, Weihua Zhai, Qiaoling Ma, Erlie Jiang, Mingzhe Han, Jiaxi Zhou, Sizhou Feng","doi":"10.1097/BS9.0000000000000121","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000121","url":null,"abstract":"<p><p>To investigate the risk factors for cytomegalovirus (CMV) infection within 100 days and the relationship between early CMV infection and 1-year relapse for patients with acute leukemia following allogeneic hematopoietic stem cell transplantation (allo-HSCT).</p><p><strong>Methods: </strong>Three hundred fifty-nine patients with acute leukemia who received allo-HSCT at our center between January 2015 and January 2020 were retrospectively reviewed.</p><p><strong>Results: </strong>Of 359 patients, 48.19% (173) patients experienced CMV infection within 100 days posttransplantation. In univariate and multivariate logistic analysis, haploidentical-related donor (HRD) (<i>P</i> < 0.001; odds ratio [OR], 5.542; 95% confidence interval [CI], 3.186-9.639), and ratio of CD3<sup>+</sup>CD8<sup>+</sup> cells in lymphocytes <14.825% (<i>P</i> < 0.001; OR, 3.005; 95% CI, 1.712-5.275) were identified as 2 independent risk factors. One-year relapse rate (RR) between the CMV infection group and the non-CMV infection group was not statistically significant (18.5% vs 19.9%, <i>P</i> = 0.688). When we divided the total cohort into AML, ALL, and MAL subgroups, there were no significant differences as well (<i>P</i> = 0.138; <i>P</i> = 0.588; <i>P</i> = 0.117; respectively).</p><p><strong>Conclusion: </strong>In conclusion, donor type (HRD) and the insufficient recovery of CD3<sup>+</sup>CD8<sup>+</sup> cells were independent risk factors for CMV infection within 100 days posttransplantation in patients with acute leukemia. CMV infection within 100 days did not influence the incidence of relapse in 1 year for patients with acute leukemia.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"164-169"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/84/bs9-4-164.PMC9742110.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10712771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RNA-binding proteins (RBPs) are widely involved in the transcriptional and posttranscriptional regulation of multiple biological processes. The transcriptional regulatory ability of RBPs was indicated by the identification of chromatin-enriched RBPs (Che-RBPs). One of these proteins, KH-type splicing regulatory protein (KHSRP), is a multifunctional RBP that has been implicated in mRNA decay, alternative splicing, and miRNA biogenesis and plays an essential role in myeloid differentiation by facilitating the maturation of miR-129. In this study, we revealed that KHSRP regulates monocytic differentiation by regulating gene transcription and RNA splicing. KHSRP-occupied specific genomic sites in promoter and enhancer regions to regulate the expression of several hematopoietic genes through transcriptional activation and bound to pre-mRNA intronic regions to modulate alternative splicing during monocytic differentiation. Of note, KHSRP had co-regulatory effects at both the transcriptional and posttranscriptional levels on MOGOH and ADARB1. Taken together, our analyses revealed the dual DNA- and RNA-binding activities of KHSRP and have provided a paradigm to guide the analysis of other functional Che-RBPs in different biological systems.
rna结合蛋白(rbp)广泛参与多种生物过程的转录和转录后调控。通过鉴定染色质富集的rbp (che - rbp)来表明rbp的转录调控能力。其中一种蛋白kh型剪接调节蛋白(KHSRP)是一种多功能RBP,与mRNA衰变、选择性剪接和miRNA生物发生有关,并通过促进miR-129的成熟在髓细胞分化中发挥重要作用。在本研究中,我们发现KHSRP通过调控基因转录和RNA剪接来调控单核细胞的分化。khsrp占据启动子和增强子区域的特定基因组位点,通过转录激活来调节几种造血基因的表达,并与mrna前内含子区域结合,在单核细胞分化过程中调节选择性剪接。值得注意的是,KHSRP在转录和转录后水平上对MOGOH和ADARB1具有共同调控作用。总之,我们的分析揭示了KHSRP的双重DNA和rna结合活性,并为不同生物系统中其他功能che - rbp的分析提供了一个范例。
{"title":"KHSRP combines transcriptional and posttranscriptional mechanisms to regulate monocytic differentiation.","authors":"Jiayue Xu, Dongsheng Wang, Hongliu Ma, Xueying Zhai, Yue Huo, Yue Ren, Weiqian Li, Le Chang, Dongxu Lu, Yuehong Guo, Yanmin Si, Yufeng Gao, Xiaoshuang Wang, Yanni Ma, Fang Wang, Jia Yu","doi":"10.1097/BS9.0000000000000122","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000122","url":null,"abstract":"<p><p>RNA-binding proteins (RBPs) are widely involved in the transcriptional and posttranscriptional regulation of multiple biological processes. The transcriptional regulatory ability of RBPs was indicated by the identification of chromatin-enriched RBPs (Che-RBPs). One of these proteins, KH-type splicing regulatory protein (KHSRP), is a multifunctional RBP that has been implicated in mRNA decay, alternative splicing, and miRNA biogenesis and plays an essential role in myeloid differentiation by facilitating the maturation of miR-129. In this study, we revealed that KHSRP regulates monocytic differentiation by regulating gene transcription and RNA splicing. KHSRP-occupied specific genomic sites in promoter and enhancer regions to regulate the expression of several hematopoietic genes through transcriptional activation and bound to pre-mRNA intronic regions to modulate alternative splicing during monocytic differentiation. Of note, KHSRP had co-regulatory effects at both the transcriptional and posttranscriptional levels on MOGOH and ADARB1. Taken together, our analyses revealed the dual DNA- and RNA-binding activities of KHSRP and have provided a paradigm to guide the analysis of other functional Che-RBPs in different biological systems.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"103-115"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10731051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1097/BS9.0000000000000131
Rong Yin, Yashu Li, Wen Tian, Fuling Zhou, Haojian Zhang
N6-Methyladenosine (m6A) is the most abundant modification in eukaryotic mRNA, and plays important biological functions via regulating RNA fate determination. Recent studies have shown that m6A modification plays a key role in hematologic malignancies, including acute myeloid leukemia. The current growth of epitranscriptomic research mainly benefits from technological progress in detecting RNA m6A modification in a transcriptome-wide manner. In this review, we first briefly summarize the latest advances in RNA m6A biology by focusing on writers, readers, and erasers of m6A modification, and describe the development of high-throughput methods for RNA m6A mapping. We further discuss the important roles of m6A modifiers in acute myeloid leukemia, and highlight the identification of potential inhibitors for AML treatment by targeting of m6A modifiers. Overall, this review provides a comprehensive summary of RNA m6A biology in acute myeloid leukemia.
{"title":"RNA m<sup>6</sup>A modification: Mapping methods, roles, and mechanisms in acute myeloid leukemia.","authors":"Rong Yin, Yashu Li, Wen Tian, Fuling Zhou, Haojian Zhang","doi":"10.1097/BS9.0000000000000131","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000131","url":null,"abstract":"<p><p>N<sup>6</sup>-Methyladenosine (m<sup>6</sup>A) is the most abundant modification in eukaryotic mRNA, and plays important biological functions via regulating RNA fate determination. Recent studies have shown that m<sup>6</sup>A modification plays a key role in hematologic malignancies, including acute myeloid leukemia. The current growth of epitranscriptomic research mainly benefits from technological progress in detecting RNA m<sup>6</sup>A modification in a transcriptome-wide manner. In this review, we first briefly summarize the latest advances in RNA m<sup>6</sup>A biology by focusing on writers, readers, and erasers of m<sup>6</sup>A modification, and describe the development of high-throughput methods for RNA m<sup>6</sup>A mapping. We further discuss the important roles of m<sup>6</sup>A modifiers in acute myeloid leukemia, and highlight the identification of potential inhibitors for AML treatment by targeting of m<sup>6</sup>A modifiers. Overall, this review provides a comprehensive summary of RNA m<sup>6</sup>A biology in acute myeloid leukemia.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"116-124"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10712764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1097/BS9.0000000000000117
Dingrui Nie, Cunte Chen, Yangqiu Li, Chengwu Zeng
Regulated cell death (RCD) is essential for maintaining cell homeostasis and preventing diseases. Besides classical apoptosis, several novel nonapoptotic forms of RCD including NETosis, pyroptosis, ferroptosis, and cuproptosis have been reported and are increasingly being implicated in various cancers and inflammation. Disulfiram (DSF), an aldehyde dehydrogenase inhibitor, has been used clinically for decades as an anti-alcoholic drug. New studies have shown that DSF possesses potent anti-inflammatory and anti-cancer effects by regulating these new types of RCD. Here, we summarize the mechanisms and discuss the potential application of DSF in the treatment of cancers and inflammatory diseases.
{"title":"Disulfiram, an aldehyde dehydrogenase inhibitor, works as a potent drug against sepsis and cancer via NETosis, pyroptosis, apoptosis, ferroptosis, and cuproptosis.","authors":"Dingrui Nie, Cunte Chen, Yangqiu Li, Chengwu Zeng","doi":"10.1097/BS9.0000000000000117","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000117","url":null,"abstract":"<p><p>Regulated cell death (RCD) is essential for maintaining cell homeostasis and preventing diseases. Besides classical apoptosis, several novel nonapoptotic forms of RCD including NETosis, pyroptosis, ferroptosis, and cuproptosis have been reported and are increasingly being implicated in various cancers and inflammation. Disulfiram (DSF), an aldehyde dehydrogenase inhibitor, has been used clinically for decades as an anti-alcoholic drug. New studies have shown that DSF possesses potent anti-inflammatory and anti-cancer effects by regulating these new types of RCD. Here, we summarize the mechanisms and discuss the potential application of DSF in the treatment of cancers and inflammatory diseases.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"152-154"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10731048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1097/BS9.0000000000000119
Xi Zhang
Hematopoietic stem-cell transplantation (HSCT) is an important, potentially curative therapeutic option for hema-tological malignancies. However, poor and slow hematopoi- etic reconstitution remains a significant complication, which is correlated with abnormal hematopoietic stem-cell (HSC) func- tion. The maintenance and the preservation of HSC functional properties are supported by a highly specialized microenviron- ment within the bone marrow (BM), in which BM-derived mesenchymal stem cells (BMSCs) serve as the essential structural and functional basis for constituting the BM microenviron-ment. Damage, such as that due to chemotherapy, radiother- apy or inflammation, delays hematopoietic recovery or causes hematopoiesis dysfunction or failure, seriously affecting HSCT efficacy. 1 The key to remodeling and repairing the BM micro-environment lies in the repair of the niche structure by cellular therapies which include BMSCs. Research has increasingly confirmed that the most crucial functions of BMSCs are to main- tain the turnover of the BM stroma and skeletal tissues and to provide critical hematopoietic support. 2 However, the underly-ing mechanisms that regulate these different functions are not well known. In the recent BLOOD publication, the Dr. Zhao and Dr. Jiang group revealed that the retinoic acid-inducible gene I (RIG-I) plays a substantial role in regulating the stromal niche for hematopoietic reconstitution. 3 All-trans retinoic acid (ATRA) and inflammation stress upregulated RIG-I expres- sion, thus damaging the clonogenicity, the bone-forming ability of BMSCs and the supporting function in the stromal niche; mechanistically, this is achieved by suppressing the antioxidant impact of nuclear
{"title":"Beyond the horizon: the newly found sinner disturbing mesenchymal stromal niche.","authors":"Xi Zhang","doi":"10.1097/BS9.0000000000000119","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000119","url":null,"abstract":"Hematopoietic stem-cell transplantation (HSCT) is an important, potentially curative therapeutic option for hema-tological malignancies. However, poor and slow hematopoi- etic reconstitution remains a significant complication, which is correlated with abnormal hematopoietic stem-cell (HSC) func- tion. The maintenance and the preservation of HSC functional properties are supported by a highly specialized microenviron- ment within the bone marrow (BM), in which BM-derived mesenchymal stem cells (BMSCs) serve as the essential structural and functional basis for constituting the BM microenviron-ment. Damage, such as that due to chemotherapy, radiother- apy or inflammation, delays hematopoietic recovery or causes hematopoiesis dysfunction or failure, seriously affecting HSCT efficacy. 1 The key to remodeling and repairing the BM micro-environment lies in the repair of the niche structure by cellular therapies which include BMSCs. Research has increasingly confirmed that the most crucial functions of BMSCs are to main- tain the turnover of the BM stroma and skeletal tissues and to provide critical hematopoietic support. 2 However, the underly-ing mechanisms that regulate these different functions are not well known. In the recent BLOOD publication, the Dr. Zhao and Dr. Jiang group revealed that the retinoic acid-inducible gene I (RIG-I) plays a substantial role in regulating the stromal niche for hematopoietic reconstitution. 3 All-trans retinoic acid (ATRA) and inflammation stress upregulated RIG-I expres- sion, thus damaging the clonogenicity, the bone-forming ability of BMSCs and the supporting function in the stromal niche; mechanistically, this is achieved by suppressing the antioxidant impact of nuclear","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"179-180"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/9b/bs9-4-179.PMC9742105.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10731050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}